IRIS-DES
Evaluation of Effectiveness and Safety of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
Sponsor study identifier
observational
50,000
1 country
1
Study Start
January 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the "real world" daily practice.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2009
Date type not reportedThis date has not been verified as actual or estimated.
August 19, 2010
Actual (reported)August 23, 2010
Actual (reported)December 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)
at 12 months post procedure
Death (all-cause and cardiac)
at 12 months and annually up to 5 years
Myocardial infarction
at 12 months and annually up to 5 years
Stent thrombosis
at 12 months and annually up to 5 years
Target-lesion and target-vessel revascularization
at 12 months and annually up to 5 years
Stroke
at 12 months and annually up to 5 years
consecutive patients receiving CYPHER stent
consecutive patients receiving Xience stent
consecutive patients receiving GENOUS stent
consecutive patients receiving PROMUS-ELEMENT stent
consecutive patients receiving XIENCE-PRIME stent
consecutive patients receiving NOBORI stent
consecutive patients receiving RESOLUTE-INTEGRITY stent
consecutive patients receiving XIENCE-XPEDITION stent
consecutive patients receiving BIOMATRIX stent
consecutive patients amenable to PCI
Korean centres
Multiple Locations, South Korea
Kim TO, Kang DY, Ahn JM, Kim MJ, Lee PH, Kim H, Choi Y, Lee J, Lee JM, Jo HH, Park YS, Lim SM, Park SJ, Park DW. Impact of Target Lesion Revascularization on Long-Term Mortality After Percutaneous Coronary Intervention for Left Main Disease. JACC Cardiovasc Interv. 2024 Jan 8;17(1):32-42. doi: 10.1016/j.jcin.2023.10.068.
Jeong YJ, Hyun J, Lee J, Kim JH, Yang Y, Choe K, Lee JS, Park H, Cho SC, Kang DY, Lee PH, Ahn JM, Park DW, Park SJ; IRIS-DES Registry Investigators. Comparison of Contemporary Drug-Eluting Stents in Patients Undergoing Complex High-Risk Indicated Procedures. JACC Asia. 2022 Mar 1;2(2):182-193. doi: 10.1016/j.jacasi.2021.10.008. eCollection 2022 Apr.
Seung-Jung Park, MD
Asan Medical Center
First Submitted
August 19, 2010
First Posted
August 23, 2010
Study Start
January 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
consecutive patients receiving CILOTAX stent
consecutive patients receiving Drug eluting balloon
consecutive patients receiving DESYNE stent
consecutive patients receiving PROMUS-PREMIER stent
consecutive patients receiving ORSIRO stent
consecutive patients receiving ONYX stent
consecutive patients receiving Bioresorbable Vascular Scaffold
consecutive acute myocardial infarction patients receiving Bioresorbable Vascular Scaffold
consecutive patients receiving Ultimaster stent
consecutive patients receiving Synergy stent
consecutive patients receiving Biofreedom stent
consecutive patients receiving Firehawk stent
consecutive patients receiving DESyne X2 stent
consecutive patients receiving Sierra stent
consecutive patients receiving Tansei stent
consecutive patients receiving Synergy XD or Synergy Megatron™ stent
consecutive patients receiving Xience-Skypoint stent
consecutive patients receiving Coroflex ISAR NEO stent
Contact the study team to confirm eligibility.
Yang Y, Hyun J, Lee J, Kim JH, Lee JB, Kang DY, Lee PH, Ahn JM, Park DW, Park SJ; IRIS-DES Registry Investigators. Effectiveness and Safety of Contemporary Drug-Eluting Stents in Patients With Diabetes Mellitus. JACC Asia. 2021 Sep 21;1(2):173-184. doi: 10.1016/j.jacasi.2021.07.009. eCollection 2021 Sep.
Park S, Ahn JM, Kim TO, Park H, Cho SC, Kang DY, Lee PH, Park DW, Park SJ; IRIS-DES Registry Investigators. Incidence and Impact of Thrombocytopenia in Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2020 Nov 1;134:55-61. doi: 10.1016/j.amjcard.2020.07.059. Epub 2020 Aug 16.
Park H, Ahn JM, Kang DY, Lee JB, Park S, Ko E, Cho SC, Lee PH, Park DW, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park SJ. Optimal Stenting Technique for Complex Coronary Lesions: Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation. JACC Cardiovasc Interv. 2020 Jun 22;13(12):1403-1413. doi: 10.1016/j.jcin.2020.03.023. Epub 2020 May 27.
Lee CH, Ahn JM, Lee KS, Kang DY, Lee PH, Lee SW, Lee CW, Park SW, Park DW, Park SJ; IRIS-DES Registry Investigators. Prevalence, predictors, prognostic significance, and effect of techniques on outcomes of coronary lesion calcification following implantation of drug-eluting stents: a patient-level pooled analysis of stent-specific, multicenter, prospective IRIS-DES registries. Coron Artery Dis. 2021 Jan;32(1):42-50. doi: 10.1097/MCA.0000000000000896.
Lee CH, Kang DY, Han M, Hur SH, Rha SW, Her SH, Seung KB, Kim KS, Lee PH, Ahn JM, Lee SW, Park SW, Park DW, Park SJ; IRIS-DES Registry Investigators. Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients. Int J Cardiol. 2019 May 1;282:17-23. doi: 10.1016/j.ijcard.2019.01.108. Epub 2019 Feb 2.
Lee PH, Kwon O, Ahn JM, Lee CH, Kang DY, Lee JB, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park DW, Park SJ. Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease. J Am Coll Cardiol. 2018 Feb 27;71(8):832-841. doi: 10.1016/j.jacc.2017.12.032.
December 2030
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
June 30, 2026
Record last verified: 2026-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: